Carlos Silva

Dr. Carlos Silva

LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2016 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
CSCarlos Silva
Carlos Silva
Diana PintoDiana Pinto
Diana Pinto
Artur M. S. SilvaArtur M. S. Silva
Artur M. S. Silva

9 July 2018 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
CSCarlos Silva
Carlos Silva
VBVasco Batista
Vasco Batista
Diana PintoDiana Pinto
Diana Pinto
Artur M. S. SilvaArtur M. S. Silva
Artur M. S. Silva
Chromones (4H-chromen-4-ones, 4H-1-benzopyran-4-ones, or benzo-γ-pyrones) are a class of oxygen-containing heterocyclic compounds. Several members of the important flavonoid class of natural compou...

26 January 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CSCarlos Silva
Carlos Silva
Diana PintoDiana Pinto
Diana Pinto
Pedro Alexandrino FernandesPedro Alexandrino Fernandes
Pedro Alexandrino Fernandes
Artur M. S. SilvaArtur M. S. Silva
Artur M. S. Silva
Nowadays, leishmaniasis constitutes a public health issue in more than 88 countries, affecting mainly people from the tropics, subtropics, and the Mediterranean area. Every year, the prevalence of this infectious disease increases, with the appearance of 1.5–2 million new cases of cutaneous leishmaniasis and 500,000 cases of visceral leishmaniasis, endangering approximately 350 million people worldwide. Therefore, the absence of a vaccine or effective treatment makes the discovery and development of new antileishmanial therapies one of the focuses for the scientific community that, in association with WHO, hopes to eradicate this disease shortly. This paper is intended to highlight the relevance of nitrogen- and oxygen-containing tricyclic heterocycles, particularly acridine and xanthene derivatives, for the development of treatments against leishmaniasis. Thus, in this review, a thorough compilation of the most promising antileishmanial acridine and xanthene derivatives is performed from both natural and synthetic origins. Additionally, some structure–activity relationship studies are also depicted and discussed to provide insight into the optimal structural features responsible for these compounds’ antileishmanial activity.

25 October 2018 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
CSCarlos Silva
Carlos Silva
Diana PintoDiana Pinto
Diana Pinto
Artur M. S. SilvaArtur M. S. Silva
Artur M. S. Silva
Introduction: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder responsible for the great majority of age-related dementias affecting daily life through memory loss and cognitive impairment. From a molecular point of view, the most common neuropathological characteristics found in AD patients are abnormal protein deposits, particularly senile plaques (SP) and neurofibrillary tangles (NFT). Furthermore, the currently available pharmacological treatment only provides short-term improvements and is focused on the use of cholinesterase (ChEs) inhibitors or memantine, an approved medicine that is a glutamatergic N-methyl-D-aspartate (NMDA) receptor blocker. Areas covered: This review is focused on the relevance of chromones for future AD treatment. Structure-activity relationship (SAR) studies which look at the inhibition of amyloid-β (Aβ) plaque formation and aggregation and the inhibition of both acetylcholinesterase (AChE) and butyrylcholinesterase are also discussed. Expert opinion: SAR studies are a useful strategy for the elucidation of structural features that improve compound-specific AD-related activities. The development of multi-target-directed ligands (MTDLs) represents an exciting challenge for organic chemists. As such, recently developed chromone-type compounds have a potential use as MTDLs for the treatment of AD.

22 July 2024 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
FLFatima Ezzahra Laghchioua
Fatima Ezzahra Laghchioua
CSCarlos Silva
Carlos Silva
Diana PintoDiana Pinto
Diana Pinto
JCJosé Cavaleiro
José Cavaleiro
Ricardo MendesRicardo Mendes
Ricardo Mendes
Nuno M. M. MouraNuno M. M. Moura
Nuno M. M. Moura
Alzheimer's disease is characterized by a progressive deterioration of cognitive function and memory loss, and it is closely associated with the dysregulation of cholinergic neurotransmission. Since acetylcholinesterase (AChE) is a critical enzyme in the nervous system, responsible for breaking down the neurotransmitter acetylcholine, its inhibition holds a significant interest in the treatment of various neurological disorders. Therefore, it is crucial to develop efficient AChE inhibitors capable of increasing acetylcholine levels, ultimately leading to improved cholinergic neurotransmission. The results reported here represent a step forward in the development of novel thiazoloindazole-based compounds that have the potential to serve as effective AChE inhibitors. Molecular docking studies revealed that certain of the evaluated nitroindazole-based compounds outperformed donepezil, a well-known AChE inhibitor used in Alzheimer's disease treatment. Sustained by these findings, two series of compounds were synthesized. One series included a triazole moiety (Tl45a-c), while the other incorporated a carbazole moiety (Tl58a-c). These compounds were isolated in yields ranging from 66 to 87% through nucleophilic substitution and Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reactions. Among the synthesized compounds, the thiazoloindazole-based 6b core derivatives emerged as selective AChE inhibitors, exhibiting remarkable IC50 values of less than 1.0 μM. Notably, derivative Tl45b displays superior performance as an AChE inhibitor, boasting the lowest IC50 (0.071 ± 0.014 μM). Structure-activity relationship (SAR) analysis indicated that derivatives containing the bis(trifluoromethyl)phenyl-triazolyl group demonstrated the most promising activity against AChE, when compared to more rigid substituents such as carbazolyl moiety. The combination of molecular docking and experimental synthesis provides a suitable and promising strategy for the development of new efficient thiazoloindazole-based AChE inhibitors.

22 February 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CSCarlos Silva
Carlos Silva
Diana PintoDiana Pinto
Diana Pinto
Pedro Alexandrino FernandesPedro Alexandrino Fernandes
Pedro Alexandrino Fernandes
Artur M. S. SilvaArtur M. S. Silva
Artur M. S. Silva
Since the beginning of the XXI century, Leishmaniasis has been integrated into the World Health Organization’s list of the 20 neglected tropical diseases, being considered a public health issue in more than 88 countries, especially in the tropics, subtropics, and the Mediterranean area. Statistically, this disease presents a world prevalence of 12 million cases worldwide, with this number being expected to increase shortly due to the 350 million people considered at risk and the 2–2.5 million new cases appearing every year. The lack of an appropriate and effective treatment against this disease has intensified the interest of many research groups to pursue the discovery and development of novel treatments in close collaboration with the WHO, which hopes to eradicate it shortly. This paper intends to highlight the quinoline scaffold’s potential for developing novel antileishmanial agents and provide a set of structural guidelines to help the research groups in the medicinal chemistry field perform more direct drug discovery and development programs. Thus, this review paper presents a thorough compilation of the most recent advances in the development of new quinoline-based antileishmanial agents, with a particular focus on structure–activity relationship studies that should be considerably useful for the future of the field.